Market Intelligence: EquiTrak Pro
Product: EquiTrak Pro | Focus: B&V
Global ENT B&V Market (TAM)
$340M
+8.4% CAGR
Taevas Markets (SAM)
$28M
+11.2% CAGR
Taevas Serviceable (SOM)
$12M
18 markets Y3
3-Year Revenue Projection
$3.8M
Country-Level Analysis
| Market | Segment Size | CAGR | Competitors | Reg. Path | Price Band | Opportunity Score | Priority |
|---|---|---|---|---|---|---|---|
| 🇮🇳 India | $8.2M | +14% | 3 (fragmented) | CDSCO Class B | ₹9-16L | 89 | High |
| 🇦🇪 UAE | $3.1M | +11% | 2 (low) | MOHAP single-window | AED 22-38K | 84 | High |
| 🇹🇭 Thailand | $2.4M | +9% | 2 | Thai FDA Class II | THB 280-520K | 71 | Medium |
| 🇸🇬 Singapore | $1.8M | +8% | 1 | HSA Class B | SGD 12-22K | 68 | Medium |
| 🇧🇩 Bangladesh | $0.9M | +19% | 0 (none) | DGDA | TBD | 62 | Watch |
AI Market Insights
- India highest priority due to largest addressable market + Taevas existing hospital relationships
- UAE low competition + fast regulatory pathway = quick win
- Thailand requires local clinical validation before launch